An observational study in Metabolic Dysfunction-Associated Steatotic Liver Disease, Major Adverse Cardiovascular Events and Liver Fibrosis, sponsored by First Affiliated Hospital Xi'an Jiaotong University. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by First Affiliated Hospital Xi'an Jiaotong University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 216 studies in Liver Cirrhosis with a site in China — 66 open to participants now, 74 under way, 4 of them phase 3. Liver Cirrhosis · China.
Among the 216 studies in Liver Cirrhosis with a site in China, this one has the largest planned enrollment of the 88 observational ones that give a count, is one of 21 that started in 2026, is one of 88 observational ones, reaches primary completion later than 73 of the 73 other live ones, and was the 215th registered.
1,303 studies on the registry are indexed under Liver Cirrhosis; 340 are open to participants now.
Browse Liver Cirrhosis studies →66 of the 216 studies in Liver Cirrhosis with a site in China are open now. Recruiting first, the newest first:
Fifth Affiliated Hospital, Sun Yat-Sen University · Sites in China
Ages 18+
Air Force Military Medical University, China · Sites in China
Ages 18+
Northern Jiangsu People's Hospital · Sites in China
Ages 18–80
The Fifth Affiliated Hospital of Wenzhou Medical University & Lishui Central Hospital · Sites in China
Ages 30–80
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Sites in China
Ages 18–80
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 208 Liver Cirrhosis studies recruiting now, 101 (49%) set no upper age limit and 66 (32%) stop at 75 or younger; 12 take children under 18; 25 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
216 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 25 · Phase 3 12 · Phase 4 22
First in 2005; this study’s year is marked. 21 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50,000 is above the median of 171 across 527 observational studies indexed under Liver Cirrhosis.
Median enrollment 120 across the 127 interventional studies, 461 across the 88 observational. Of the 61 that completed or were terminated, 6 (10%) have results posted.
This tab as a report to print or save as PDF → With an account.
24 of 216 have an industry lead sponsor. The 10 most frequent:
First Affiliated Hospital Xi'an Jiaotong University is the lead sponsor of 317 studies on the registry; 90 are open to participants now.
First Affiliated Hospital Xi'an Jiaotong University has 4 studies filed under Liver Cirrhosis — fewer than ten, so there is no comparison to draw.
14 of the studies in Liver Cirrhosis with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06779058Shengjing HospitalMR Elastography for Assessing Liver Fibrosis in Chronic Hepatitis B | 2026-12-01 |
| NCT06770283Second Affiliated Hospital, School of Medicine, Zhejiang UniversitySpirulina Tablets Treat Liver Fibrosis/Cirrhosis | 2026-12-26 |
| NCT07252102Zhejiang UniversityEffect of HFNC on Incidence of Hypoxia During Sedated Gastrointestinal Endoscopy in Critical Patients | 2026-12-28 |
| NCT05974904Chongqing Medical UniversityAssociation of HsCAR with MAFLD and Liver Fibrosis: a Cross-sectional Study | 2026-12-28 |
| NCT06762223Xiqiao ZhouHenagliflozin on Liver Fibrosis in Patients with MASLD and T2DM | 2026-12-31 |
Add all 14 to your calendar (.ics) → With an account.
Among the 216 studies in Liver Cirrhosis with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this observational study is to investigate the relationship between liver health and cardiovascular diseases in adults. The study aims to understand how liver fat, liver scarring, and other liver changes are related to heart structure, heart function, and cardiovascular events over time.
The main questions it aims to answer are:
Researchers will study two groups of participants: a retrospective cohort, using existing medical records and imaging data, and a prospective cohort, following participants over time.
Participants in the prospective cohort will have their medical information, laboratory results, and imaging findings collected during routine care. They will also provide blood and other biological samples, with informed consent, for future research. Researchers will follow participants to assess changes in liver health, heart function, and cardiovascular outcomes. No study treatment will be assigned, and participants will continue to receive their usual medical care.
The liver and cardiovascular system have complex and bidirectional interactions. The liver plays an important role in glucose and lipid metabolism, inflammation, blood clotting, and the production of circulating proteins and metabolic factors. Abnormal liver metabolism, fat accumulation, and liver fibrosis may be associated with the development and progression of cardiovascular diseases. Conversely, cardiovascular dysfunction, particularly heart failure and elevated venous pressure, may contribute to liver injury and fibrosis.
However, the longitudinal relationships between liver abnormalities, cardiac structural and functional changes, and long-term cardiovascular outcomes remain incompletely understood. In particular, large-scale studies integrating liver imaging, cardiac imaging, clinical laboratory results, longitudinal follow-up, and biological samples are limited.
The Cardiohepatic Cohort (CHC) is a multicenter, observational, ambispective, real-world cohort study led by the First Affiliated Hospital of Xi'an Jiaotong University. The study aims to establish an integrated research platform to investigate the bidirectional relationship between liver health and cardiovascular diseases.
The study consists of two cohorts:
**Study Population and Data Collection**
The study will include adults aged 18 years or older with relevant clinical information. The prospective cohort will include participants with cardiovascular diseases, metabolic disorders, and individuals undergoing abdominal imaging examinations.
Data collected will include:
**Follow-up and Clinical Outcomes**
Participants in the prospective cohort will undergo follow-up according to the study schedule, including assessments at 3, 6, 12, 24, 36, 48, and 60 months after enrollment. Follow-up will include clinical status, treatment changes, laboratory results, electrocardiographic findings, cardiac imaging, liver-related assessments, and cardiovascular events. Follow-up information will be obtained through outpatient visits, hospital records, telephone interviews, and electronic medical records.
The primary research focus is the longitudinal association between liver-related phenotypes and cardiovascular outcomes. Major adverse cardiovascular events (MACE) will include cardiovascular death, myocardial infarction, ischemic stroke, and hospitalization for heart failure.
Other important cardiovascular outcomes will include incident atrial fibrillation, new-onset heart failure, coronary artery disease events, and malignant ventricular arrhythmias.
Secondary assessments will include changes in cardiac structure and function, such as left atrial volume index, left ventricular ejection fraction, diastolic function, and ventricular remodeling parameters. Electrocardiographic outcomes will include atrial fibrillation burden, premature ventricular contractions, complex arrhythmias, and heart rate variability. Changes in liver imaging phenotypes, cardiac imaging findings, rehospitalization, and all-cause mortality will also be evaluated.
**Biological Sample Collection and Exploratory Mechanistic Studies**
In the prospective cohort, biological samples will be collected with informed consent according to the study protocol. These may include peripheral blood, urine, and stool samples. Additional tissue or body fluid samples, such as liver tissue, myocardial tissue, thrombi, and pericardial fluid, may be collected when available from clinically indicated procedures or routine medical care. The study will not require additional invasive procedures solely for research sample collection.
Selected samples and representative participant subgroups will be used for exploratory analyses, including proteomics, metabolomics, inflammatory biomarker measurements, and other molecular studies. These investigations aim to identify potential biological pathways linking liver abnormalities with cardiovascular injury and remodeling.
**Overall Study Objectives**
The Cardiohepatic Cohort aims to:
This is an observational study. No investigational treatment or intervention will be assigned. Participants will continue to receive medical care according to their treating physicians' decisions. The study will provide a comprehensive real-world research platform for understanding the liver-heart axis and supporting future cardiovascular risk assessment and precision medicine.
Adults aged 18 years or older receiving medical care at the First Affiliated Hospital of Xi'an Jiaotong University and participating centers will be included. The retrospective cohort will identify eligible participants from existing electronic medical records, laboratory databases, imaging systems, and follow-up records, requiring at least one abdominal imaging examination or documented liver-related assessment. The prospective cohort will consecutively enroll eligible adults with cardiovascular diseases, metabolic abnormalities, or those undergoing abdominal imaging, with standardized longitudinal follow-up. Participants will receive routine clinical care without study-assigned interventions. Biospecimen collection and exploratory molecular analyses will be optional and subject to appropriate informed consent or ethical approval. Lack of biospecimens will not exclude participants from the clinical cohort.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Adults aged 18 years or older. Receiving medical care at the participating centers, with available clinical information relevant to liver and cardiovascular assessments, including demographic characteristics, clinical diagnoses, and laboratory data.
For the retrospective cohort: at least one abdominal imaging examination or documented liver-related assessment during the relevant observation period.
For the prospective cohort: individuals receiving care for cardiovascular diseases, metabolic abnormalities, or undergoing abdominal imaging examinations, who are able to complete standardized longitudinal follow-up.
For the prospective cohort: willingness and ability to participate in the study and provide written .
Exclusion Criteria:
Advanced or an expected survival time of less than 6 months. Severe active infection, acute inflammatory conditions, or other conditions at enrollment that may substantially interfere with the assessment of the principal study measures.
Active viral hepatitis, severe liver disease, or other specific liver diseases that may substantially confound the evaluation of liver-related metabolic phenotypes.
For the retrospective cohort: insufficient key clinical information to establish eligibility or ascertain the primary study outcomes.
For the prospective cohort: inability or unwillingness to participate in standardized longitudinal follow-up or refusal to provide written .
Note: Participation in biospecimen collection and exploratory molecular analyses is optional and is not a requirement for enrollment in the overall clinical cohort. Refusal or inability to provide biological samples will not affect eligibility for the clinical cohort or participation in clinical follow-up.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This cohort includes eligible adults aged 18 years or older who previously received medical care at participating centers. Existing electronic medical records, laboratory results, abdominal and cardiac imaging data, treatment information, and follow-up records will be retrospectively collected and analyzed. Liver-related phenotypes, cardiovascular risk factors, cardiac structure and function, and long-term cardiovascular outcomes will be evaluated. Previously collected biological samples may be used when available and ethically approved. No additional clinical procedures or interventions will be performed.
This cohort includes eligible adults aged 18 years or older who will be consecutively enrolled at participating centers. Baseline clinical characteristics, liver-related laboratory measurements, abdominal imaging findings, cardiac assessments, and treatment information will be collected. Participants will undergo longitudinal follow-up to assess changes in liver health, cardiac structure and function, and cardiovascular outcomes. With informed consent, blood and other biological samples will be collected and stored for future biomarker, multi-omics, and exploratory mechanistic analyses. No investigational treatment will be assigned, and routine clinical care will remain unchanged.
Time to First Major Adverse Cardiovascular Event (MACE)
Time from baseline to the first occurrence of a major adverse cardiovascular event (MACE), defined as a composite of cardiovascular death, myocardial infarction, ischemic stroke, or hospitalization for heart failure. The primary measure is the time to the first qualifying event, expressed in days. Only the first qualifying event will be counted. Events will be identified through medical records and follow-up information.
Time frame: From baseline to the first qualifying event, assessed for up to 60 months.
Number of Participants With New-Onset Heart Failure
Number of participants without heart failure at baseline who develop clinically documented heart failure during follow-up. Heart failure will be identified through documented clinical diagnoses and supporting medical records, including available cardiac imaging and laboratory findings. The measure will be the number of participants experiencing at least one qualifying event.
Time frame: From baseline to the first documented diagnosis of heart failure, assessed for up to 60 months.
Number of Participants With New-Onset Atrial Fibrillation
Number of participants without documented atrial fibrillation at baseline who develop atrial fibrillation during follow-up. Atrial fibrillation will be confirmed by electrocardiography, ambulatory electrocardiographic monitoring, or documented clinical diagnosis supported by available electrocardiographic records. The measure will be the number of participants with at least one confirmed event.
Time frame: From baseline to the first documented diagnosis of atrial fibrillation, assessed for up to 60 months.
Number of Participants With Malignant Ventricular Arrhythmia Events
Number of participants experiencing at least one clinically documented malignant ventricular arrhythmia event during follow-up, including sustained ventricular tachycardia, ventricular fibrillation, or cardiac arrest attributable to ventricular arrhythmia. Events will be identified through electrocardiographic documentation, medical records, cardiac monitoring, and available implanted device records.
Time frame: From baseline to the first qualifying event, assessed for up to 60 months.
Number of Participants With Coronary Artery Disease Events
Number of participants experiencing at least one clinically documented coronary artery disease event during follow-up. Events are defined as myocardial infarction or hospitalization for unstable angina. Event ascertainment will be based on clinical diagnoses, hospitalization records, and available diagnostic findings.
Time frame: From baseline to the first qualifying coronary artery disease event, assessed for up to 60 months.
Number of Participants With Unplanned All-Cause Hospital Readmission
Number of participants experiencing at least one unplanned hospital readmission for any cause following discharge from the index hospitalization. Readmission will be identified through hospital records and follow-up information. Planned admissions and scheduled procedures will be excluded. This measure will be assessed only among participants with an identifiable index hospitalization and discharge date.
Time frame: From discharge after the index hospitalization to the first unplanned readmission, assessed for up to 60 months.
Time to All-Cause Death (Days)
Time from baseline to death from any cause, expressed in days. Vital status and date of death will be determined using available medical records and follow-up information.
Time frame: From baseline to death or the end of follow-up, assessed for up to 60 months.
Change From Baseline in Left Atrial Volume Index (mL/m²)
Change from baseline in left atrial volume index (LAVI), measured by transthoracic echocardiography and expressed in mL/m². LAVI will be calculated by indexing left atrial volume to body surface area. The change will be calculated as the follow-up value minus the baseline value among participants with available measurements.
Time frame: Baseline and follow-up assessments at months 3, 6, 12, 24, 36, 48, and 60, when available.
Change From Baseline in Left Ventricular Ejection Fraction (Percentage Points)
Change from baseline in left ventricular ejection fraction (LVEF), measured by transthoracic echocardiography and expressed in percentage points. LVEF will be determined using available echocardiographic measurements. The change will be calculated as the follow-up value minus the baseline value among participants with available measurements.
Time frame: Baseline and follow-up assessments at months 3, 6, 12, 24, 36, 48, and 60, when available.
Number of Participants With a Change in Imaging-Defined Hepatic Steatosis Status
Number of participants with a change in hepatic steatosis status between baseline and follow-up imaging. Hepatic steatosis will be assessed using available abdominal ultrasound, computed tomography, or magnetic resonance imaging according to standardized imaging criteria. Status changes will be classified as new-onset, resolved, persistent, or absent. Longitudinal comparisons will prioritize the same imaging modality, and quantitative measurements from different modalities will not be directly combined.
Time frame: Baseline and available follow-up imaging assessments through 60 months.
Change From Baseline in Fibrosis-4 Index (FIB-4 Score)
Change from baseline in the Fibrosis-4 Index (FIB-4), a unitless noninvasive score calculated using age, aspartate aminotransferase, alanine aminotransferase, and platelet count. FIB-4 estimates the risk of advanced liver fibrosis. The change will be calculated as the follow-up score minus the baseline score. Results will be interpreted as changes in estimated fibrosis-related risk rather than direct evidence of histological fibrosis progression or regression.
Time frame: Baseline and available follow-up laboratory assessments through 60 months.
Change From Baseline in Serum Alanine Aminotransferase (ALT, U/L)
Change from baseline in serum alanine aminotransferase (ALT) concentration, measured using routine clinical laboratory assays and expressed in U/L. The change will be calculated as the follow-up ALT concentration minus the baseline concentration among participants with available measurements.
Time frame: Baseline and available follow-up laboratory assessments at months 3, 6, 12, 24, 36, 48, and 60, when available.
Relative Abundance of Circulating Proteins Measured by Mass Spectrometry (Log2-Transformed Intensity)
Relative abundance of circulating proteins in available stored blood samples, measured using mass spectrometry-based proteomic analysis (LC-MS/MS). Protein abundance will be expressed as normalized, log2-transformed protein intensity in arbitrary units. The same normalized intensity scale will be used for each protein analyzed. Exploratory analyses will investigate associations between circulating protein abundance, liver-related phenotypes, cardiac structural and functional changes, and cardiovascular outcomes. Analyses will be conducted in selected participants with available biospecimens and appropriate informed consent or ethical approval.
Time frame: Baseline and available follow-up biospecimen assessments through 60 months.
Relative Abundance of Circulating Metabolites Measured by Mass Spectrometry (Log2-Transformed Intensity)
Relative abundance of circulating metabolites in available stored blood samples, measured using mass spectrometry-based metabolomic analysis (LC-MS/MS). Metabolite abundance will be expressed as normalized, log2-transformed peak intensity in arbitrary units. The same normalized intensity scale will be used for each metabolite analyzed. Exploratory analyses will investigate associations between circulating metabolite abundance, liver-related phenotypes, cardiac structural and functional changes, and cardiovascular outcomes. Analyses will be conducted in selected participants with available biospecimens and appropriate informed consent or ethical approval.
Time frame: Baseline and available follow-up biospecimen assessments through 60 months.
Start is estimated for Nov 2026; primary completion for Aug 2046, 236 months later.
Of 231 non-industry observational studies under Liver Cirrhosis, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 71. This study's planned 236 months is above that.
Counting every sponsor, half of 247 studies reached it within 47 months; a quarter within 18 and three quarters within 71.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
First Affiliated Hospital Xi'an Jiaotong University →